Risk Factors for No-Reflow in Patients with ST-Elevation Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Case-Control Study

被引:10
作者
Yu, Ying [1 ]
Wu, Yongquan [1 ]
Wu, Xianyi [2 ]
Wang, Jinwen [3 ]
Wang, Changhua [1 ]
机构
[1] Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Beijing, Peoples R China
[2] Peoples Liberat Army Gen Hosp, Daytime Diag & Treatment Dept, Med Ctr 5, Beijing, Peoples R China
[3] Beijing Inst Heart Lung & Blood Vessel Dis, Beijing, Peoples R China
关键词
C-REACTIVE PROTEIN; ANGIOGRAPHIC ASSESSMENT; SEGMENT ELEVATION; PROGNOSTIC VALUE; RATIO PREDICTS; HYPERGLYCEMIA; REPERFUSION; PREALBUMIN; MANAGEMENT; SERUM;
D O I
10.1155/2022/3482518
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives. The no-reflow phenomenon is a poor prognosis for patients with ST-elevation myocardial infarction (STEMI) who underwent percutaneous coronary intervention (PCI). The purpose of this study was to identify the risk factors for no-reflow in patients with STEMI who underwent PCI. Methods. This case-control study retrospectively reviewed the medical data of patients treated with primary percutaneous coronary intervention within 12 h after STEMI onset between January 2010 and January 2013 at the Department of Cardiology of the Beijing Anzhen Hospital. Results. A total of 902 patients were included in the analysis. The basic characteristics between the reflow and no-reflow groups were similar, except for time-to-hospital admission, heart rate, plasma glucose, high-sensitivity C-reactive protein (hsCRP)/prealbumin (PAB), neutrophil count, intraaortic balloon pump, and aspiration thrombectomy. The multivariable analysis showed that hsCRP/PAB (OR = 1.003, 95% CI: 1.000-1.006, P=0.022), neutrophil count (OR = 1.085, 95% CI: 1.028-1.146, P=0.003), plasma glucose levels (OR = 1.086, 95% CI: 1.036-1.138, P=0.001), diabetes mellitus (OR = 0.596, 95% CI: 0.371-0.958, P=0.033), Killip classification > 1 (OR = 2.002, 95% CI: 1.273-3.148, P=0.003), intraoperative intraaortic balloon pump (IABP) use (OR = 3.257, 95% CI: 1.954-5.428, P=0.001), and aspiration thrombectomy (OR = 3.412, 95% CI: 2.259-5.152, P=0.001) were independently associated with no-reflow. Conclusion. hsCRP/PAB, neutrophil count, plasma glucose levels, diabetes mellitus, Killip classification, intraoperative IABP use, and aspiration thrombectomy were independent risk factors for no-reflow in patients with STEMI.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Relationship between Hemoglobin Concentration at Admission with the Incidence of No-Reflow Phenomenon and In-Hospital Mortality in Acute Myocardial Infarction with Elevation of ST Segments in Patients who underwent Primary Percutaneous Coronary Intervention
    Akbar, Kiagus Muhammad Andri
    Dharma, Surya
    Andriantoro, Hananto
    Sukmawan, Renan
    Mangkuanom, Arwin Saleh
    Rejeki, Vidya Gilang
    INTERNATIONAL JOURNAL OF ANGIOLOGY, 2023, 32 (02) : 106 - 112
  • [22] Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary Intervention
    Larson, David M.
    Duval, Sue
    Sharkey, Scott S.
    Solie, Christopher
    Tschautscher, Craig
    Lips, Daniel L.
    Burke, M. Nicholas
    Steinhubl, Steven
    Henry, Timothy D.
    AMERICAN HEART JOURNAL, 2010, 160 (01) : 202 - 207
  • [23] Navigating the Risk Landscape in ST-Elevation Myocardial Infarction Patients Post-percutaneous Coronary Intervention: A Narrative Review
    Gaur, Utkarsh
    Gadkari, Charuta
    Pundkar, Aditya
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2025, 19 (01) : OE1 - OE6
  • [24] Impact of maintenance dose of eptifibatide in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention
    Jalalian, Rozita
    Bagheri, Babak
    Charati, Jamshid Yazdani
    Khalaghi, Shahrnaz
    Iranian, Mohammadreza
    Mohammadi, Mahsa
    EGYPTIAN HEART JOURNAL, 2023, 75 (01)
  • [25] Predictors and outcomes of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
    Tasar, Onur
    Karabay, Arzu K.
    Oduncu, Vecih
    Kirma, Cevat
    CORONARY ARTERY DISEASE, 2019, 30 (04) : 270 - 276
  • [26] A Risk Score for No Reflow in Patients With ST-Segment Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention
    Wang, Jin-Wen
    Zhou, Zi-Qiang
    Chen, Yun-Dai
    Wang, Chang-Hua
    Zhu, Xiao-ling
    CLINICAL CARDIOLOGY, 2015, 38 (04) : 208 - 215
  • [27] RDW as A Predictor for No-Reflow Phenomenon in DM Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
    Sun, Ying
    Ren, Jian
    Li, Li
    Wang, Chunsong
    Yao, Hengchen
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (03)
  • [28] J-waves in patients with an acute ST-elevation myocardial infarction who underwent successful percutaneous coronary intervention: prevalence, pathogenesis, and clinical implication
    Nakayama, Masafumi
    Sato, Masahito
    Kitazawa, Hitoshi
    Saito, Atsushi
    Ikeda, Yoshio
    Fujita, Satoru
    Fuse, Koichi
    Takahashi, Minoru
    Takarada, Ken
    Oguro, Takeo
    Matsushita, Hirooki
    Okabe, Masaaki
    Yamashina, Akira
    Aizawa, Yoshifusa
    EUROPACE, 2013, 15 (01): : 109 - 115
  • [29] Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial
    Welsh, Robert C.
    Sidhu, Robinder S.
    Cairns, John A.
    Lavi, Shahar
    Kedev, Sasko
    Moreno, Raul
    Cantor, Warren J.
    Stankovic, Goran
    Meeks, Brandi
    Yuan, Fei
    Dzavik, Vladimir
    Jolly, Sanjit S.
    CANADIAN JOURNAL OF CARDIOLOGY, 2019, 35 (10) : 1377 - 1385
  • [30] Direct intracoronary delivery of tirofiban during primary percutaneous coronary intervention for ST-elevation myocardial infarction
    Shen Wei-feng
    CHINESE MEDICAL JOURNAL, 2012, 125 (01) : 3 - 6